drugset
drugset / Trial / NCT03787004

A Placebo-Controlled, Two-Part Study, Oral Dose to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CNTX-6970 in Healthy Subjects

NCT03787004 ↗

Phase 1 Completed 62 enrolled Centrexion Therapeutics
RandomizedParallel-groupOpen-labelTreatment

Summary

A Phase 1, placebo-controlled, two part study with either single dose or multiple increasing oral dose to evaluate the safety, pharmacokinetics, and pharmacodynamics of CNTX-6970 in healthy subjects.

Timeline

Start
2017-08-14
Primary completion
2018-08-19
Completion
2018-09-26

Drugs

EvaluationDrugModalityDoseRoute
Subject CNTX-6970 Small molecule 100 mg Oral
Subject CNTX-6970 Small molecule 300 mg Oral
Subject CNTX-6970 Small molecule 600 mg Oral

Indications

chronic pain syndrome